OBJECTIVESThe aim of this scoping review was to evaluate the available scientific evidence regarding the use of flavonoids in the treatment of caries-affected dentin focusing on bonding to dentin.METHODSA comprehensive literature search was performed in five databases from March 2022 and updated in April 2023: PubMed, EMBASE, Scopus, Web of Science, and Scielo. Additionally, the references of included studies were manually searched. Gray literature was excluded from the review.STUDY SELECTIONInclusion criteria included in vitro, in situ, and in vivo studies (animal or human) published in English. Abstracts, reviews, case reports, book chapters, doctoral dissertations, guidelines, and studies using pure plant extracts were excluded. Data collected from the selected studies were summarized and subjected to narrative and descriptive analysis. Out of the 91 studies identified, only 16 studies met the inclusion criteria.RESULTSThe review analyzed eight different flavonoids (hesperidin, galardin, proanthocyanidin, genipin, quercetin, naringin, epigallocatechin-3-gallate, and other catechins subtypes) used as pretreatment or loaded into adhesive systems, primers, and phosphoric acid. The use of flavonoids improved the mechanical properties of the materials and modified the biological properties of the dentin, reducing collagen loss by the inhibition of proteolytic activity of matrix metalloproteinases (MMPs).CONCLUSIONSBased on the findings of this scoping review, it can be concluded that the use of flavonoids as pretreatment or incorporation into dental materials preserves collagen in the hybrid layer, inhibiting the MMPs activities, modifying the collagen fibrils of the dentin matrix and improving the mechanical properties of the dental adhesive systems. Therefore, it represents a promising approach for promoting dentin biomodification. This can result in more stable bonding of adhesive restorations to caries-affected dentin.

2024-05-01·Neurochemical Research

Epidermal Growth Factor Suppresses the Development of GABAergic Neurons Via the Modulation of Perineuronal Net Formation in the Neocortex of Developing Rodent Brains

Article

作者: Kobayashi, Yutaro ; Nawa, Hiroyuki ; Namba, Hisaaki ; Iwakura, Yuriko ; Takei, Nobuyuki

Previously, we reported that epidermal growth factor (EGF) suppresses GABAergic neuronal development in the rodent cortex. Parvalbumin-positive GABAergic neurons (PV neurons) have a unique extracellular structure, perineuronal nets (PNNs). PNNs are formed during the development of PV neurons and are mainly formed from chondroitin sulfate (CS) proteoglycans (CSPGs). We examined the effect of EGF on CSPG production and PNN formation as a potential molecular mechanism for the inhibition of inhibiting GABAergic neuronal development by EGF. In EGF-overexpressing transgenic (EGF-Tg) mice, the number of PNN-positive PV neurons was decreased in the cortex compared with that in wild-type mice, as in our previous report. The amount of CS and neurocan was also lower in the cortex of EGF-Tg mice, with a similar decrease observed in EGF-treated cultured cortical neurons. PD153035, an EGF receptor (ErbB1) kinase inhibitor, prevented those mentioned above excess EGF-induced reduction in PNN. We explored the molecular mechanism underlying the effect of EGF on PNNs using fluorescent substrates for matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinases (ADAMs). EGF increased the enzyme activity of MMPs and ADAMs in cultured neurons. These enzyme activities were also increased in the EGF-Tg mice cortex. GM6001, a broad inhibitor of MMPs and ADAMs, also blocked EGF-induced PNN reductions. Therefore, EGF/EGF receptor signals may regulate PNN formation in the developing cortex.

2024-04-10·ACS Applied Materials & Interfaces

Curcumin-Based Ionic Liquid Hydrogel for Topical Transdermal Delivery of Curcumin To Improve Its Therapeutic Effect on the Psoriasis Mouse Model

Article

作者: Lu, Beibei ; Zhang, Jianglin ; Zhang, Jiaheng ; Zhong, Yixiu

Psoriasis is a systemic, recurrent, chronic autoimmune skin disease. However, psoriasis drugs have poor skin permeability and high toxicity, resulting in low bioavailability and affecting their clinical application. In this study, we propose a curcumin-based ionic liquid hydrogel loaded with ilomastat (Cur-Car-IL@Ilo hydrogel), which can effectively maintain the sustained release of drugs and improve the skin permeability of drugs. We used a model of imiquimod-induced psoriasis and demonstrated that local application of Cur-Car-IL@Ilo hydrogel can improve skin lesions in mice with significantly reduced expression levels of inflammatory factors, matrix metalloproteinase 8, and collagen-I. The expressions of iron death-related proteins SLC7A11 and ASL4 were significantly decreased after treatment with Cur-Car-IL@Ilo hydrogel. Flora analysis showed that the content of anaerotruncus, proteus, and UCG-009 bacteria in the gut of psoriatic mice increased. The levels of paludicola, parabacteroides, prevotellaceae_UCG-001, escherichia-shigella, and aerococcus decreased, and the levels of some of the above bacteria tended to be normal after treatment. Therefore, the curcumin-based ionic liquid hydrogel can be used as a multifunctional, nonirritating, noninvasive, and highly effective percutaneous treatment of psoriasis.

100 项与伊洛马司他相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03793	-	-	DB02255

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
角膜溃疡	临床3期	-	University of Florida	-
角膜溃疡	临床3期	-	Arriva Pharmaceuticals, Inc.	-
角膜溃疡	临床3期	美国	Ligand Pharmaceuticals, Inc.	-
角膜溃疡	临床3期	-	Quick-Med Technologies, Inc.	-
糖尿病性视网膜病变	临床3期	美国	Ligand Pharmaceuticals, Inc.	-
肿瘤	临床3期	美国	Ligand Pharmaceuticals, Inc.	-
慢性阻塞性肺疾病	临床3期	美国	Arriva Pharmaceuticals, Inc.	-
化学性烧伤	临床1期	以色列	Quick-Med Technologies, Inc.	-
化学性烧伤	临床1期	美国	Quick-Med Technologies, Inc.	-
化学性烧伤	药物发现	荷兰	Quick-Med Technologies, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ARVO2003	N/A	青光眼 Matrix Metalloproteinases	-	Ilomastat	(鹽構壓淵壓壓範鏇簾艱) = 鑰淵廠膚鬱鑰鹹淵繭鬱繭鹽顧築鏇鑰憲鹹齋築 (醖艱選糧廠網鑰蓋蓋膚 )	积极	2003-05-01
				Mitomycin-C	(鹽構壓淵壓壓範鏇簾艱) = 遞鹽鹽願顧齋衊鬱襯夢繭鹽顧築鏇鑰憲鹹齋築 (醖艱選糧廠網鑰蓋蓋膚 )
ARVO2010	N/A	-	-	Ilomastat Tissue Tablet	齋鏇蓋艱構壓鑰餘襯鬱(鬱襯艱壓齋觸襯鏇顧鬱) = 範顧遞範築壓選積餘觸觸衊鹽鬱網鹽夢鏇廠繭 (淵齋簾選顧衊繭選鹹窪 ) 更多	-	2010-04-01
				Ilomastat	齋鏇蓋艱構壓鑰餘襯鬱(鬱襯艱壓齋觸襯鏇顧鬱) = 願蓋餘窪餘觸構壓糧鏇觸衊鹽鬱網鹽夢鏇廠繭 (淵齋簾選顧衊繭選鹹窪 ) 更多
ARVO2010	N/A	Matrix Metalloproteinases (MMPs) 2	-	GM6001	(觸壓構遞構齋蓋襯艱餘) = 壓築觸餘簾觸網繭壓醖網廠鏇淵淵獵廠製窪獵 (鹽襯繭齋餘鬱構鹹願遞 )	-	2010-04-01
ARVO2002	N/A	-	40	Galardin	(鑰鑰築繭壓範鹹鬱觸齋) = 鑰構鑰鬱簾繭遞醖積醖積獵鹹壓鹽襯觸膚膚鑰 (醖鏇鹽艱蓋憲簾糧鏇繭 )	积极	2002-12-01
				Phosphate buffered saline (PBS)	(鑰鑰築繭壓範鹹鬱觸齋) = 餘繭遞願鏇繭餘觸壓窪積獵鹹壓鹽襯觸膚膚鑰 (醖鏇鹽艱蓋憲簾糧鏇繭 )
ARVO2006	N/A	-	-	Ilomastat	(選繭襯窪遞膚顧鹽餘廠) = 蓋鏇網醖憲蓋遞糧顧願鏇糧網範壓鏇築窪壓鏇 (築糧鹹選廠範鑰簾繭壓 )	-	2006-05-01
				Ilomastat	(選繭襯窪遞膚顧鹽餘廠) = 積網廠築顧襯繭積窪糧鏇糧網範壓鏇築窪壓鏇 (築糧鹹選廠範鑰簾繭壓 )
209473 (ARVO2007)	N/A	matrix metalloproteinases (MMP)	-	MK801	(獵築範鑰網窪製膚積鏇) = 衊醖壓憲範衊顧憲壓鹽夢廠襯襯糧範簾窪選淵 (範網鹹襯積蓋製顧膚遞 )	-	2007-05-01
				GYKI52466	(獵築範鑰網窪製膚積鏇) = 鑰鏇製遞範鑰蓋壓簾積夢廠襯襯糧範簾窪選淵 (範網鹹襯積蓋製顧膚遞 )